JP2012515754A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515754A5
JP2012515754A5 JP2011546964A JP2011546964A JP2012515754A5 JP 2012515754 A5 JP2012515754 A5 JP 2012515754A5 JP 2011546964 A JP2011546964 A JP 2011546964A JP 2011546964 A JP2011546964 A JP 2011546964A JP 2012515754 A5 JP2012515754 A5 JP 2012515754A5
Authority
JP
Japan
Prior art keywords
drug
medicament
compounds
composition
glycosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011546964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515754A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2010/050098 external-priority patent/WO2010084356A1/en
Publication of JP2012515754A publication Critical patent/JP2012515754A/ja
Publication of JP2012515754A5 publication Critical patent/JP2012515754A5/ja
Pending legal-status Critical Current

Links

JP2011546964A 2009-01-24 2010-01-22 神経栄養因子介在疾患の治療 Pending JP2012515754A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14708409P 2009-01-24 2009-01-24
US61/147,084 2009-01-24
CNPCT/CN2009/070319 2009-01-24
CN2009070319 2009-01-24
PCT/GB2010/050098 WO2010084356A1 (en) 2009-01-24 2010-01-22 Treatment of neurotrophic factor mediated disorders

Publications (2)

Publication Number Publication Date
JP2012515754A JP2012515754A (ja) 2012-07-12
JP2012515754A5 true JP2012515754A5 (enExample) 2013-03-07

Family

ID=41800830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546964A Pending JP2012515754A (ja) 2009-01-24 2010-01-22 神経栄養因子介在疾患の治療

Country Status (12)

Country Link
US (1) US20120034193A1 (enExample)
EP (1) EP2389182A1 (enExample)
JP (1) JP2012515754A (enExample)
KR (1) KR20110115589A (enExample)
AU (1) AU2010207597A1 (enExample)
BR (1) BRPI1005372A2 (enExample)
CA (1) CA2750510A1 (enExample)
EA (1) EA201190115A1 (enExample)
IL (1) IL214242A0 (enExample)
MX (1) MX2011007842A (enExample)
SG (1) SG173094A1 (enExample)
WO (1) WO2010084356A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543482A (ja) * 2010-07-20 2013-12-05 ファイトファーム ピーエルシー Ｌ−ドーパ、ドーパミン作動薬及び／又はドーパミン賦活剤により誘発される疾患の処置
US8708906B1 (en) * 2011-09-07 2014-04-29 Allen J. Orehek Method for the prevention of dementia and Alzheimer's disease
RU2501562C1 (ru) * 2012-11-01 2013-12-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук ФГБУ "НИИ фармакологии" СО РАМН Средство, обладающее церебропротекторной активностью
US20160193296A1 (en) * 2012-12-19 2016-07-07 Brown University Methods for treatment of microcephaly associated autism disorders
WO2017218697A1 (en) * 2016-06-17 2017-12-21 The Trustees Columbia University In The City Of New York Identification of compounds that target the rna-binding protein tia-1 an important regulator of stress vulnerability in both mice and humans
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
JP2019526607A (ja) * 2016-09-12 2019-09-19 ユニバーシティ・オブ・サウス・フロリダ ケトンにより改善された神経再生
CA3046415A1 (en) 2016-12-21 2018-06-28 Universitats-Kinderspital Beider Basel Migraine prevention and treatment
US20180177753A1 (en) * 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
EP3663309B1 (en) * 2017-08-01 2024-01-03 Gomes, Lisis Rojo Steroidal glycosides from furcraea foetida plant extracts for treating skin disorders
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
US11617772B2 (en) 2018-09-11 2023-04-04 Direct Digital Llc Nutritional supplements and therapeutic compositions comprising probiotics
WO2021195477A1 (en) 2020-03-27 2021-09-30 Ketoneaid, Inc. Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections
KR102779301B1 (ko) 2021-12-13 2025-03-13 한국한의약진흥원 근위축 개선, 예방 또는 치료용 조성물
CN115282156A (zh) * 2022-09-05 2022-11-04 广东海洋大学 知母皂苷元在制备防治帕金森病的药物中的应用
KR102553713B1 (ko) * 2022-11-18 2023-07-10 고덕상 미네랄 촉매제를 이용한 양식어류사료 제조방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0102416A1 (en) 1982-08-23 1984-03-14 Nutrisearch Company Blends of egg albumen and whey protein of improved gel strength
DK1017379T3 (en) 1997-03-17 2015-02-16 Btg Int Ltd Therapeutic compositions comprising ketone compounds and precursors thereof
CN1131237C (zh) 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
EP1066033B1 (en) 1998-03-26 2005-12-28 Phytopharm Plc Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
DK1123094T3 (da) 1998-09-15 2007-08-20 Btg Int Ltd Terapeutiske præparater (II)
GB9923078D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US7795218B2 (en) * 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
DE10162058A1 (de) * 2001-12-17 2003-07-24 Cospharcon Gmbh Gefäßaktive, juckreiz- und entzündungslindernde Zubereitung zur Minimierung der unangenehmen Begleiterscheinungen hämorrhoidaler Affekte und Ekzeme im Analbereich sowie als unterstützende Maßnahme zur Intertrigo- und Dekubitus-Prophylaxe bei entsprechend disponierten Personen.
PL213697B1 (pl) 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
JP4573157B2 (ja) * 2002-03-27 2010-11-04 フィトファーム・パブリック・リミテッド・カンパニー 治療方法ならびにサポゲニンおよびその誘導体の使用
US7354956B2 (en) * 2002-04-12 2008-04-08 L'oreal Composition containing a sapogenin and use thereof
US20050100531A1 (en) * 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
PL1706121T3 (pl) * 2004-01-12 2009-02-27 Turski Lechoslaw Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych
NZ548926A (en) * 2004-02-09 2009-07-31 Regenion Gmbh Inhibitors of TGF-R signaling for treatment of CNS disorders
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
CN1692914B (zh) 2004-04-29 2010-05-26 中国人民解放军军事医学科学院放射医学研究所 知母皂苷bⅱ在制备用于防治脑卒中药物或产品中的用途
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds

Similar Documents

Publication Publication Date Title
Guo et al. Natural products from herbal medicine self‐assemble into advanced bioactive materials
Amalraj et al. Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: a review
Lu et al. Development of organogel-derived capsaicin nanoemulsion with improved bioaccessibility and reduced gastric mucosa irritation
Deng et al. Berberine-loaded nanostructured lipid carriers enhance the treatment of ulcerative colitis
Gierlikowska et al. Inula helenium and Grindelia squarrosa as a source of compounds with anti-inflammatory activity in human neutrophils and cultured human respiratory epithelium
ES2809177T3 (es) Inhalación de levofloxacino para reducir la inflamación pulmonar
CN102802636B (zh) 藏花素水解产物
WO2020081513A1 (en) Novel compositions for the treatment of inflammatory diseases
CN102843922A (zh) 硝基脂肪酸–认知减退的神经保护和/或抑制
WO2011026401A1 (zh) 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途
Mirzaei et al. Resveratrol augments doxorubicin and cisplatin chemotherapy: a novel therapeutic strategy
Cerasoli Jr Developing the ideal inhaled corticosteroid
Nanavati Phytosome: a novel approach to enhance the bioavailability of phytoconstituent
JP2012515754A (ja) 神経栄養因子介在疾患の治療
Jacob et al. Vesicular carriers for phytochemical delivery: a comprehensive review of techniques and applications
JP2011513437A5 (enExample)
US20140271844A1 (en) Compositions containing nitro fatty acids
Bin Jardan et al. Effects of garden cress, fenugreek and black seed on the pharmacodynamics of metoprolol: An herb-drug interaction study in rats with hypertension
US20190060220A1 (en) Process and Method to Accelerate Cellular Regeneration, Healing and Wound Management
WO2013133062A1 (ja) アレルギー性鼻炎用塗付剤
JP6820323B2 (ja) 組成物及びその使用
TW201717959A (zh) 用於對金屬卟啉進行微粒遞送之調配物及用途
CN103118688B (zh) 锁阳化学成分作为植物雌激素的新用途
WO2013111729A1 (ja) 医薬組成物及びこれを用いた薬用化粧品
JP2024528332A (ja) 肺の炎症を治療するための、吸入薬物送達のための新規オメガ３担体製剤